Denali Therapeutics Inc. · NASDAQ:DNLI
Denali Therapeutics — Denali Blood-Brain Barrier Transport Vehicle Webinar (October 2020)
97 slides from Denali Therapeutics's conference presentation, Oct 15, 2020
Slide 1: Transporting Biotherapeutics Across the Blood-Brain Barrier
Transporting Biotherapeutics Across the Blood-Brain Barrier October 15, 2020
Slide 2: Disclaimers: Forward Looking Statements
Disclaimers Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including, without limitation, statements
Slide 3: Agenda
AGENDA TIME (ET) TOPIC SPEAKER 1:00 – 1:30 p.m. Introduction and Blood-Brain Barrier Transport Vehicle (TV) Overview Ryan Watts, PhD CEO, Denali Simon Jones, MRCPCH, MBChB 1:30 – 1:50 p.m. Hunter Syndrome: Overview Willink Unit, Manchester Centre for Genomic Medicine 1:50 – 2:20 p.m. TV Flagship Pro
Slide 4: Introduction
Introduction Ryan Watts, PhD, CEO
Slide 5: Our Purpose: Defeat Degeneration
OUR PURPOSE: DEFEAT DEGENERATION RARE NEURODEGENERATIVE AMYOTROPHIC DISEASES LATERAL SCLEROSIS PARKINSON’S ALZHEIMER’S Orphan 20,000+ (US) 1,000,000+ (US) 5,800,000+ (US) >30 lysosomal storage diseases >45 known genetic associations >95 known genetic associations >35 known genetic associations on Di
Slide 6: Our Principles
OUR PRINCIPLES SCIENTIFIC Genetic Pathway Potential Engineering Brain Delivery Biomarker-Driven Development BUSINESS Broad Portfolio Parallel Investments Strategic Partnering 6
Slide 7: Degenogenes Define Neurodegeneration Biology
DEGENOGENES DEFINE NEURODEGENERATION BIOLOGY Glial Biology-related Degenogenes PILRA Lysosomal Function-related Degenogenes Alzheimer’s Cellular Homeostasis-related Degenogenes Disease Other Degenogenes Number of Genetic Associations and Implicated Genes APOE4 Parkinson’s Disease ALS / FTD 7
Slide 8: Our Portfolio Approach
OUR PORTFOLIO APPROACH DIVERSE DIFFERENTIATED DATA-DRIVEN Therapeutic Pipeline Brain Delivery Technology Drug Development on Di sea y Populati se Popula alth tio He n Multiple therapeutic targets, Two Platforms: Focus on target engagement, modalities and indications in Degenogene Biology & pathway e
Slide 9: Our Progress: Past Two Years
OUR PROGRESS: PAST TWO YEARS • RIPK1 decision to advance 3Q DNL788; pause DNL747 3Q 1Q • Biomarker PoC LRRK2 inhibitors • Initiated P1/2 in Hunter syndrome (HV & PD for DNL201; HV for (ETV:IDS/DNL310) DNL151) • Sanofi initiated Ph1b COVID-19 of • IND accepted for ETV:IDS/DNL310 peripheral inhibitor
Slide 10: Our Portfolio
OUR PORTFOLIO Large Molecule (TV Platform) Small Molecule AAV DRUG DEVELOPMENT PROGRAM TARGET DRUG CANDIDATE DISEASE INDICATION PARTNER Drug Discovery IND-Enabling Early Clinical Late Clinical Approved LYSOSOMAL FUNCTION PATHWAY LRRK2 DNL151 Parkinson’s Biogen Iduronate 2-sulfatase DNL310 MPS II (Hu
Slide 11: 2020 Clinical Progress and Plans
2020 CLINICAL PROGRESS AND PLANS LRRK2 § Entered strategic collaboration with Biogen Parkinson’s § Advancing DNL151 into late-stage clinical trials in 2021 EIF2B § DNL343 Phase 1 in HV results to enable patient study – end of 2020 / early 2021 ALS RIPK1 § IND submitted for DNL788 (Sanofi) CNS § Firs
Slide 12: Blood-Brain Barrier Transport Vehicle
Blood-Brain Barrier Transport Vehicle Ryan Watts, PhD, CEO
Slide 13: Large Opportunity for Biotherapeutics in Neurological Disease
LARGE OPPORTUNITY FOR BIOTHERAPEUTICS IN NEUROLOGICAL DISEASE NEUROLOGICAL DISEASE APPROVED BIOTHERAPEUTICS Cause of #1 Disability 4 Cause of #2 Death Majority are intrathecal (IT) or intracerebroventricular (ICV) delivery* There is a significant need for blood-brain barrier (BBB) crossing biotherap
Slide 14: Key Considerations for Biotherapeutics and the Brain
KEY CONSIDERATIONS FOR BIOTHERAPEUTICS AND THE BRAIN • Brains are surrounded by cerebrospinal fluid (CSF) that circulates and is turned over many times a day • Directly injecting biotherapeutics into the brain faces major limitations Mouse • CSF flow into the brain is incomplete • Diffusion from a p
Slide 15: Widespread Biodistribution with BBB-Crossing vs Intrathecal
WIDESPREAD BIODISTRIBUTION WITH BBB-CROSSING COMPARED TO LIMITED INTRATHECAL BIODISTRIBUTION INTRATHECAL BIOTHERAPEUTIC INTRAVENOUS BBB-CROSSING BIOTHERAPEUTIC Limited distribution with sharp gradients at brain Widespread biodistribution dictated by capillary TfR and spinal cord CSF-contacting surfa
Slide 16: Increasing Brain Exposure by Targeting Transferrin Receptor
INCREASING BRAIN EXPOSURE BY TARGETING TRANSFERRIN RECEPTOR TRANSFERRIN RECEPTOR (TfR) Native biology • Actively transports iron into the brain • Plays critical role in iron homeostasis • Highly expressed on brain endothelial cells Target for brain delivery • High vascularization enables ubiquitous
Slide 17: Milestones in Developing TfR Technology
MILESTONES IN DEVELOPING TRANSFERRIN RECEPTOR (TfR) TECHNOLOGY 1980-1990 1990-2010 2010-2015 2015-2020 TfR binding transport vehicle (TV) platform brain delivery in mice and NHPs Transport Vehicle TfR MAb brain Reduced affinity Monovalent single TfR bispecific brain TfR at the BBB delivery in rats T
Slide 18: TV Technology Delivers Biotherapeutics to the Brain
TV TECHNOLOGY DELIVERS BIOTHERAPEUTICS TO THE BRAIN ATV TfR Tf Tf endothelial cell membrane Antibody Transport Vehicle (ATV) Published May 27, 2020 Brain regions (cynomolgus monkey) Cortex (cynomolgus monkey) ATV achieves high concentrations and broad distribution of antibodies in nonhuman primate b
Slide 19: Broad Biodistribution of ATV in Mouse Brain
BROAD BIODISTRIBUTION OF ATV IN MOUSE BRAIN neocortex huIgG1 NeuN huIgG1 NeuN DAPI huIgG1 NeuN huIgG1 NeuN DAPI anti-BACE1 anti-BACE1 24 hours 4 hours 20 µm 20 µm ATV35.21:BACE1 ATV35.21:BACE1 24 hours 4 hours 5 µm 5 µm Time-dependent transfer of ATV antibodies from blood vessel (left) throughout th
Slide 20: ETV Technology Delivers Enzymes to the Brain
ETV TECHNOLOGY DELIVERS ENZYMES TO THE BRAIN ETV:IDS crosses the BBB and reduces GAGs in all cell types in brain Published May 27, 2020 ETV:IDS uptake in neurons DAPI NeuN LAMP2 huIgG Colocalization Denali Data ETV achieves high concentration and broad distribution of enzymes in the brain after IV a
Slide 21: ETV:IDS Shows Broad Brain Biodistribution Compared to IgG:IDS
ETV:IDS SHOWS BROAD BRAIN BIODISTRIBUTION COMPARED TO IgG:IDS broad distribution vascular trapped ETV:IDS broad biodistribution IgG:IDS vascular trapped Denali Data; Neocortex, 10 mg/kg, n=3 per group (mean ± SEM); p values: two-way ANOVA w/ Sidak’s multiple comparison test; *** p £ 0.001 and **** p
Slide 22: Modality-Based Brain Delivery Platforms Enabled by TV
MODALITY-BASED BRAIN DELIVERY PLATFORMS ENABLED BY TV Antibody Transport Vehicle Enzyme Transport Vehicle § Deliver antibodies in bivalent or bispecific § Deliver enzymes to the brain format to the brain § Treat neuronopathic symptoms of § Natural IgG structure and properties lysosomal storage disea
Slide 23: TV Differentiation
Standard Protein Antibody Fusion Bispecific TV DIFFERENTIATION TfR binding Antibody TfR binding TfR binding Transport Vehicle TfR binding TfR Bispecific binding Antibody Single Chain Standard Protein Antibody Fusion Antibody Fusion TfR Roche binding JCR Pharma DENALI Genentech Key Biotherapeutic Pro
Slide 24: Expanding the Therapeutic Landscape with TV Delivery
EXPANDING THE THERAPEUTIC LANDSCAPE WITH TV DELIVERY ENHANCE TARGETS UNLOCK TARGETS Improved efficacy with TV Creation of new opportunities ATV:Aβ ATV:TREM2 ATV:HER2 ETV:IDS ETV:SGSH OTV PTV:PGRN (DNL310) Increase biodistribution (10-30X) and enhance Unlock brain delivery of biotherapeutics activity
Slide 25: Mucopolysaccharidosis type II (Hunter syndrome)
Mucopolysaccharidosis type II (Hunter syndrome) Simon Jones Willink Unit Manchester centre for Genomic Medicine
Slide 26: Disclosures
Disclosures • Consultant and investigator - Denali therapeutics • Consultant and investigator - Takeda • Consultant, investigator and shareholder - Orchard therapeutics • Consultant - Avrobio 26
Slide 27: Classification of MPS
Classification of MPS TYPE NAME ENZYME DEFICIENCY GAG MPS I Hurler / Scheie α-L-iduronidase HS DS MPS II Hunter Iduronate-2-sulfatase HS DS MPS IIIA Sanfilippo A Heparin sulfamidase HS MPS IIIB Sanfilippo B N-acetyl-α-D-glucosaminidase HS MPS IIIC Sanfilippo C Acetyl-CoA:α-glucosaminidase HS MPS III
Slide 28: Classification of MPS
Classification of MPS TYPE NAME ENZYME DEFICIENCY GAG MPS I Hurler / Scheie α-L-iduronidase HS DS MPS II Hunter Iduronate-2-sulfatase HS DS MPS IIIA Sanfilippo A Heparin sulfamidase HS MPS IIIB Sanfilippo B N-acetyl-α-D-glucosaminidase HS MPS IIIC Sanfilippo C Acetyl-CoA:α-glucosaminidase HS MPS III
Slide 29: Classification of MPS
Classification of MPS TYPE NAME ENZYME DEFICIENCY GAG MPS I Hurler / Scheie α-L-iduronidase HS DS MPS II Hunter Iduronate-2-sulfatase HS DS MPS IIIA Sanfilippo A Heparin sulfamidase HS MPS IIIB Sanfilippo B N-acetyl-α-D-glucosaminidase HS MPS IIIC Sanfilippo C Acetyl-CoA:α-glucosaminidase HS MPS III
Slide 30: Classification of MPS
Classification of MPS TYPE NAME ENZYME DEFICIENCY GAG MPS I Hurler / Scheie α-L-iduronidase HS DS MPS II Hunter Iduronate-2-sulfatase HS DS MPS IIIA Sanfilippo A Heparin sulfamidase HS MPS IIIB Sanfilippo B N-acetyl-α-D-glucosaminidase HS MPS IIIC Sanfilippo C Acetyl-CoA:α-glucosaminidase HS MPS III
Slide 31: Slide 31
Slide 32: Neuronopathic MPSII
Neuronopathic MPSII • Between 1 in 100,000 and 1 in 150,000 • X-linked disorder • 2/3 of boys in some way neuronopathic • No current specific treatment but for very early HSCT - infrequent • IV Elaprase used in this group to improve QOL without much evidence base and varies from country to country •
Slide 33: Neuronopathic MPSII
Neuronopathic MPSII • Most (around 50%) of cases have progressive CNS disease with developmental delay, plateau and regression • 20-30% of boys will have a static neurological disease • Behavioural and sleep disturbance common • Supportive measures relatively poor • Poor relationship between the sev
Slide 34: Intravenous Elaprase in neuronopathic MPSII
Intravenous Elaprase in neuronopathic MPSII • Usually improvements in somatic manifestations • Improved growth • Significant benefits in general well being (less infections, less pain/stiffness) • No discernible effect on cognition or prevention of dementia • Probable positive effect on survival (Ba
Slide 35: Unmet needs in MPSII
Unmet needs in MPSII • Central nervous system • Skeletal system • Heart valves • Airway (tracheal) disease • Heterogeneity and incomplete response to Elaprase • Prediction of phenotype 35
Slide 36: Role of Biomarkers
Role of Biomarkers • Obvious biomarker for somatic disease is the stored glycosaminoglycans themselves 36 Muenzer et al 2011
Slide 37: Role of Biomarkers
Role of Biomarkers • Total GAGs in urine lack sensitivity but also an ability to reflect the CNS storage burden • Direct GAG species in blood are now possible to measure but still not the brain • Direct GAG measurement in CSF (DS and HS) likely the most useful • Interpretation of these in terms of a
Slide 38: Clinical endpoints
Clinical endpoints • Neurocognitive endpoints – Consensus statements important • Behavioural/PROM/QOL important but poorly validated this far • Somatic endpoints – Spirometry – 6 minute walk test 38
Slide 39: TV Flagship Program: ETV:IDS (DNL310)
TV Flagship Program: ETV:IDS (DNL310) Carole Ho, MD, CMO & Head of Development
Slide 40: Developing a Therapy for Hunter Syndrome
DEVELOPING A THERAPY FOR HUNTER SYNDROME 40
Slide 41: Brain Delivery Is a Critical Unmet Medical Need
BRAIN DELIVERY IS A CRITICAL UNMET MEDICAL NEED IDS ETV:IDS (DNL310) aims to treat the cognitive aspects of Hunter syndrome while maintaining physical benefit transferrin in the entire body with IV administration receptor (TfR) epitope Enzyme Transport Vehicle DENALI INVESTIGATIONAL APPROACH (ETV:ID
Slide 42: ETV:IDS (DNL310) for Hunter Syndrome
ETV:IDS (DNL310) FOR HUNTER SYNDROME TARGET PATHWAY PATHOLOGY Loss of activity of IDS causes IDS deficiency reduces lysosomal Lysosomal dysfunction Hunter syndrome (MPS II) function causes inflammation and neuronal cell loss Accumulation and increased Lysosomal dysfunction and increased lipids Incre
Slide 43: ETV:IDS Biomarker-Driven Development Strategy
ETV:IDS BIOMARKER-DRIVEN DEVELOPMENT STRATEGY Target Engagement Pathway Engagement Patient Phenotyping Patient Impact Early dose finding Increase confidence in dose selection Definitive clinical data Ø Demonstrate clinical efficacy on neurocognitive endpoints Ø Engaged regulatory • Reduce • Improve
Slide 44: ETV:IDS Development Strategy and Data Overview
ETV:IDS DEVELOPMENT STRATEGY AND DATA OVERVIEW Pre-clinical Efficacy Studies (Hunter Mouse) + Fluid Biomarker Analysis* (Hunter Patients) Data today (Oct 2020) Supportive data for Clinical Observational Biomarker Study (n=28) future registration Phase 1/2 (n=~16) Interim data (end 2020) Ph2/3 Ph2/3
Slide 45: ETV:IDS Development Strategy and Data Detail
ETV:IDS DEVELOPMENT STRATEGY AND DATA DETAIL Data Today (Oct 2020) • Pre-clinical Efficacy • Target engagement (GAG reduction) • Correction of skeletal abnormalities Studies (Hunter Mouse) + • Improved lysosomal function • Improvement motor skills • Fluid Biomarker Analysis • Nf-L reduction • Rescue
Slide 46: ETV:IDS Corrects Lysosomal Function After Systemic Administration
ETV:IDS CORRECTS LYSOSOMAL FUNCTION AFTER SYSTEMIC ADMINISTRATION Published May 27, 2020 ETV:IDS reduces lysosomal lipid accumulation in the brain TfR mu/hu IDS KO model Vehicle Vehicle IDS ETV:IDS GM3 (d36:1) GM2 (d36:1) 4 week treatment, initiation of treatment at 2 months High dose PoC study with
Slide 47: Patient Phenotyping: Discovery of Patient Biomarkers
PATIENT PHENOTYPING: DISCOVERY OF PATIENT BIOMARKERS Published July, 2020 Clinical Status # Subjects Age (SD) Non-MPS Controls 25 5.8 (5.4) MPS II (on ERT) 6 3.3 (1.4) MPS II (pre and post Hematopoietic 2 1 (0) Stem Cell Transplant) 1st paper in Hunter patients to correlate abnormalities in GAGs wit
Slide 48: Target Engagement: GAG Reduction Informed by Patient Data
TARGET ENGAGEMENT: GAG REDUCTION INFORMED BY PATIENT DATA Primary storage substrate (GAGS) metabolized ETV:IDS reduces accumulated by IDS is elevated in Hunter patients substrate in Hunter IDS KO Model Serum CSF CSF Brain <2x ~ 11x CSF GAGs are elevated despite SOC Elaprase treatment 13 week treatme
Slide 49: Pathway Engagement: Ganglioside Reduction
PATHWAY ENGAGEMENT: GANGLIOSIDE REDUCTION INFORMED BY PATIENT DATA Increased gangliosides due to lysosomal ETV:IDS corrects secondary storage of GM3 and dysfunction in CSF of Hunter patients other lysosomal lipids in Hunter IDS KO Model Brain Serum CSF CSF Brain 0.006 *** 80 **** *** **** Brain GM3
Slide 50: Pathway Engagement: BMP and GluCer Reduction
PATHWAY ENGAGEMENT: BMP AND GLUCER REDUCTION INFORMED BY PATIENT DATA Increased BMP and glucosylceramide due ETV:IDS corrects lysosomal dysfunction to lysosomal dysfunction in CSF of Hunter (accumulation of BMP and Glucosylceramide) in patients Hunter IDS KO Model CSF CSF * Brain 0.3 **** (d18:1/16:
Slide 51: Biomarker of Neuroaxonal Injury Informed by Patient Data
BIOMARKER OF NEUROAXONAL INJURY INFORMED BY PATIENT DATA Increased Nf-L reflects neuroaxonal injury Nf-L increases with age in Hunter patients in Hunter IDS KO Model Serum CSF CSF ~ 6x ~ 5x ~ 5x ETV:IDS ETV:IDS Increased serum and CSF levels of Nf-L 1 2 reflects the lack of effect of SOC on neuroaxo
Slide 52: ETV:IDS Slowed Neuroaxonal Injury in Hunter KO Model
ETV:IDS SLOWED NEUROAXONAL INJURY IN HUNTER KO MODEL CSF Nf-L ETV:IDS prevents neuroaxonal injury with ETV:IDS prevents neuroaxonal injury with 1 treatment initiation at 2 months of age 2 treatment initiation at 4.5 months of age 6000 2500 ** ~ 5x *** 2000 * CSF NfL (pg/mL) ETV:IDS ETV:IDS 4000 CSF
Slide 53: ETV:IDS Improves Motor Function in Hunter KO Model
ETV:IDS IMPROVES MOTOR FUNCTION IN HUNTER KO MODEL GROSS motor impairment in Hunter patients ETV:IDS improves motor skills in mouse model Treadmill Pole Test Gross motor development Developmental age (yr) h Calendar age (yr) 17 week treatment, initiation of treatment at 4.5 months, 3mg/kg, Holt et a
Slide 54: ETV:IDS Rescues Cognitive Deficits in Hunter KO Model
ETV:IDS RESCUES COGNITIVE DEFICITS IN HUNTER KO MODEL Loss of cognitive milestones ETV:IDS normalizes spatial learning and memory in mouse model In Hunter patients TRAINING TRIALS REINSTATEMENT TRIALS Worse Developmental age (yr) cognitive development sh Cognitive performance Better Calendar age (yr
Slide 55: ETV:IDS Corrects Skeletal Disease in Hunter KO Model
ETV:IDS CORRECTS SKELETAL DISEASE IN HUNTER KO MODEL Skeletal manifestations ETV:IDS improves skeletal disease manifestations in in Hunter syndrome mouse model Vehicle Vehicle ETV:IDS TfR mu/hu IDS KO, TfR mu/hu Trabecular ROI Femur Peripheral ERT still does not Cortical ROI fully address skeletal m
Slide 56: ETV:IDS Differentiation and Best in Class Assessment
ETV:IDS DIFFERENTIATION AND BEST IN CLASS ASSESSMENT ENABLES NEURO- CSF GAG LYSOSOMAL SINGLE IV DATA ON DEGENERATION SUBSTRATE FUNCTION DELIVERY THERAPY CSF & BRAIN BIOMARKER REDUCTION IMPROVEMENT FOR PHYSICAL & CORRELATION IMPROVEMENT CNS DISEASE Denali ~50% @ 8 weeks *Animal model *Animal model ET
Slide 57: Enrolling Two Clinical Trials in Hunter Syndrome
ENROLLING TWO CLINICAL TRIALS IN HUNTER SYNDROME Observational study of Treatment Responsive Phase 1/2 study of DNL310 in children with Biomarkers in Hunter syndrome Hunter syndrome An observational study of urine, blood, and CSF biomarkers Interventional study of DNL310 in ~16 pediatric patients wi
Slide 58: DNL310 Phase 1/2 Patient Study
DNL310 PHASE 1/2 PATIENT STUDY STUDY OVERVIEW PART 1 (DOSE ESCALATION) • Neuronopathic and non-neuronopathic • Treatment naïve or on Elaprase > 4mo • Part 1 (dose escalation, 24 weeks) • Part 2 (safety extension, 18 months) 16 weeks, weekly Patients Cohort A Cohort A (5-10 yo, N= ~4 Neuronopathic) D
Slide 59: ETV:IDS Development Strategy and Data Overview
ETV:IDS DEVELOPMENT STRATEGY AND DATA OVERVIEW Preclinical Efficacy Studies (Hunter mouse) + Fluid Biomarker Analysis* (Hunter patients) Data today (Oct 2020) Supportive data for Clinical Observational Biomarker Study (n=28) future registration Phase 1/2 (n=~16) Interim data (end 2020) Ph2/3 Ph2/3 P
Slide 60: Modality-Based Brain Delivery Platforms Enabled by TV
MODALITY-BASED BRAIN DELIVERY PLATFORMS ENABLED BY TV Antibody Transport Vehicle Enzyme Transport Vehicle § Deliver antibodies in bivalent or bispecific § Deliver enzymes to the brain format to the brain § Treat neuronopathic symptoms of § Natural IgG structure and properties lysosomal storage disea
Slide 61: ETV:IDS Conclusions
ETV:IDS CONCLUSIONS • DNL310 has the potential to treat the neurologic and physical manifestations of Hunter syndrome with a single IV therapeutic, replacing current SOC • Newly identified biomarkers in Hunter animal models and patients connects GAG reduction to lysosomal rescue (lipid reduction), r
Slide 62: JENALI
JENALI
Slide 63: Break
Break
Slide 64: TV Discovery Programs
TV Discovery Programs Joe Lewcock, PhD, CSO
Slide 65: Our TV Portfolio
OUR TV PORTFOLIO DRUG DEVELOPMENT PROGRAM TARGET DRUG CANDIDATE DISEASE INDICATION PARTNER Drug Discovery IND-Enabling Early Clinical Late Clinical Approved ATV – Antibody Transport Vehicle TREM2 DNL919 Alzheimer’s Takeda Abeta ATV:Abeta Alzheimer’s Biogen Tau ATV:Tau Alzheimer’s Takeda Alpha-Synucl
Slide 66: Modality-Based Brain Delivery Platforms Enabled by TV
MODALITY-BASED BRAIN DELIVERY PLATFORMS ENABLED BY TV Antibody Transport Vehicle Enzyme Transport Vehicle § Deliver antibodies in bivalent or bispecific § Deliver enzymes to the brain format to the brain § Treat neuronopathic symptoms of § Natural IgG structure and properties lysosomal storage disea
Slide 67: Expanding the Therapeutic Landscape with TV Delivery
EXPANDING THE THERAPEUTIC LANDSCAPE WITH TV DELIVERY ENHANCE TARGETS UNLOCK TARGETS Improved efficacy with TV Creation of new opportunities ATV:Aβ ATV:TREM2 ATV:HER2 ETV:IDS ETV:SGSH OTV PTV:PGRN (DNL310) Increase biodistribution (10-30X) and enhance Unlock brain delivery of biotherapeutics activity
Slide 68: ATV:Aβ Shows Increased Brain Uptake Across Low Doses
ATV:Aβ SHOWS INCREASED BRAIN UPTAKE ACROSS LOW DOSES 1d DESIGN TfRms/hu : IV of 1, 3, or 10 mg/kg 5XFAD; TfRms/hu Brain 15 TfRms/hu 5XFAD; TfRms/hu ATV:Aβ No Aβ Plaques Aβ Plaques Present **** 10 huIgG [nM] ** cisLALA **** 5 ** **** 0 Aβ V Aβ V Aβ V Aβ V Aβ V Aβ V AT AT AT AT AT AT α- α- α- α- α- α-
Slide 69: ATV:Aβ Shows Increased Plaque Decoration Across Low Doses
ATV:Aβ SHOWS INCREASED PLAQUE DECORATION ACROSS LOW DOSES 1d DESIGN TfRms/hu : IV of 1, 3, or 10 mg/kg 5XFAD; TfRms/hu 10mg/kg Anti-Aβ 10mg/kg ATV:Aβ Aβ Plaques huIgG Aβ + huIgG Colocalization 0.4 TfRmu/hu 5XFAD; TfRmu/hu 17.0x ** % Aβ huIgG Colocalization 0.3 % Colocalization 0.2 16.1x * 0.1 15.6x
Slide 70: TREM2 Therapeutic Hypothesis
TREM2 THERAPEUTIC HYPOTHESIS: IMPROVE MICROGLIAL FUNCTION THROUGH ENHANCEMENT OF TREM2 ACTIVITY Lipids & Apo-/Lipoproteins mutations (e.g. R47H) TREM2 ADAM10/17 cleavage site microglial cell membrane DAP12 PIP2 OH DAG P P IP3 P SYK SYK P PLCȖ2 P P ITAM • Lipid processing • Phagocytosis • Transcripti
Slide 71: ATV:TREM2 Induces Robust Pharmacodynamic Response in Brain
ATV:TREM2 INDUCES ROBUST PHARMACODYNAMIC RESPONSE IN BRAIN Single Dose - 10 mg/kg Brain huIgG ATV:Isotype TREM2 Antibody ATV:TREM2 4 Antibody concentration [nM] Iba1 3 ATV:TREM2 2 1 0 2 2 EM EM TR RT V: AT Multi Dose – Matched Brain Exposure 100 Brain huIgG 8 Iba+ Microglia **** **** Brain concentra
Slide 72: TV Has Applications Outside of Neurodegeneration
TV HAS APPLICATIONS OUTSIDE OF NEURODEGENERATION Brain huIgG Concentration Growth Inhibition 50 mg/kg, 24h post dose HER2+ OE19 cells 60 150 ATV:HER2 Untreated trastuzumab ATV:tras **** Brain huIgG (nM) % Cell Viability 40 **** 100 20 50 0 0 0.01 0.1 1 10 100 1000 ab as ab r pe tr um m V: V: zu Conc
Slide 73: TV Has Applications Outside of Neurodegeneration
TV HAS APPLICATIONS OUTSIDE OF NEURODEGENERATION Brain huIgG Concentration HER2+ Xenograft (BT474) 50 mg/kg, 24h post dose trastuzumab + pertuzumab 60 ATV:HER2 150 ATV:tras + ATV:per **** % Tumor Growth Inhibition **** ** Brain huIgG (nM) ns 40 **** 100 50 20 0 0 3+3 10 + 10 20 + 20 ab as ab r pe tr
Slide 74: Modality-Based Brain Delivery Platforms Enabled by TV
MODALITY-BASED BRAIN DELIVERY PLATFORMS ENABLED BY TV Antibody Transport Vehicle Enzyme Transport Vehicle § Deliver antibodies in bivalent or bispecific § Deliver enzymes to the brain format to the brain § Treat neuronopathic symptoms of § Natural IgG structure and properties lysosomal storage disea
Slide 75: ETV Enables CNS Delivery of Additional Lysosomal Enzymes
ETV ENABLES CNS DELIVERY OF ADDITIONAL LYSOSOMAL ENZYMES Brain Heparan Sulfate CSF Heparan Sulfate **** **** 20 Total Heparan Sulfate (ng/ug) Total Heparan Sulfate (ng/uL) ETV:SGSH ns **** 9 15 (D0A0, D0S0) ** (D0A0, D0S0) 6 **** 10 5 3 0 0 SH le le SH SH le le SH ic ic ic ic G G h h G G h h Ve Ve :
Slide 76: ETV Platform Has Broad Potential for Many Lysosomal Storage Diseases
ETV PLATFORM HAS BROAD POTENTIAL FOR MANY LYSOSOMAL STORAGE DISEASES ETV:IDS (Hunter) ETV:SGSH (MPS IIIA) ETV:LF1 ~ 2,500 – 4,000 Patients (US) Other Lysosomal Storage Diseases with CNS Pathology ~ 10,000+ Patients (US) Denali has expanded portfolio with initiation of two additional ETV programs for
Slide 77: Modality-Based Brain Delivery Platforms Enabled by TV
MODALITY-BASED BRAIN DELIVERY PLATFORMS ENABLED BY TV Antibody Transport Vehicle Enzyme Transport Vehicle § Deliver antibodies in bivalent or bispecific § Deliver enzymes to the brain format to the brain § Treat neuronopathic symptoms of § Natural IgG structure and properties lysosomal storage disea
Slide 78: Progranulin Deficiency Results in Lysosomal Dysfunction
PROGRANULIN DEFICIENCY RESULTS IN LYSOSOMAL DYSFUNCTION GENETICS PATHWAY PATHOLOGY Mutations in GRN result in decreased PGRN deficiency dysregulates Lysosomal dysfunction causes levels of protein lysosomal function inflammation and neuronal cell loss PGRN (human CSF) Nf-L (human CSF) PGRN LAMP1 * *
Slide 79: Lipidomics Identifies Altered BMP Levels in GRN KO Mouse Brain
LIPIDOMICS IDENTIFIES ALTERED BMP LEVELS IN GRN KO MOUSE BRAIN Brain BMP BRAIN: Grn KO vs. Grn WT p-value (unadjusted) 0.001 Brain Lysosomal Lipid 0.01 0.05 1 Lower in Grn KO Elevated in Grn KO 20 30 50 80 100 125 200 300 500 Percent WT (%) PGRN deficiency reveals lipid changes indicative of lysosom
Slide 80: BMP Is a Unique Phospholipid Enriched in Endolysosomes
BMP IS A UNIQUE PHOSPHOLIPID ENRICHED IN ENDOLYSOSOMES Bis(monoacylglycero)phosphate (BMP) • Phospholipid concentrated in the intraluminal vesicles (ILVs) of late endosomes and lysosomes • Also found on exosomes and can therefore be detected in extracellular environment and biofluids • Hypothesized
Slide 81: PTV:PGRN Restores Lysosomal Function in Brain
PTV:PGRN RESTORES LYSOSOMAL FUNCTION IN BRAIN Brain BMP Liver BMP PTV:PGRN PTV:PGRN PTV:PGRN but not Fc:PGRN rescues Brain BMP levels in Grn KO mice data shown as mean ± s.e.m.; **** p < 0.0001 81 One-way ANOVA, Sidak’s multiple comparison correction
Slide 82: PTV:PGRN Provides Sustained Rescue of Lysosomal Function
PTV:PGRN PROVIDES SUSTAINED RESCUE OF LYSOSOMAL FUNCTION AND MICROGLIAL ACTIVATION High dose 1, 3, 7, 10 days Brain huIgG Brain BMP Brain Trem2 Drug Concentration Lysosome Dysfunction Microglial Activation NR GP :VT P Grn KO Grn WT Grn WT Grn KO Rescue of BMP and TREM2 levels maintained after PTV:PG
Slide 83: PTV:PGRN Provides Sustained Rescue of Lysosomal Function
PTV:PGRN PROVIDES SUSTAINED RESCUE OF LYSOSOMAL FUNCTION AND MICROGLIAL ACTIVATION High dose 1, 3, 7, 10 days Low dose 2, 3, 6 weeks Brain huIgG Brain BMP Brain BMP Drug Concentration Lysosome Dysfunction Lysosome Dysfunction NR GP :VT P Grn WT Grn WT Grn KO Grn KO Weeks after IV Dosing Rescue of BM
Slide 84: CSF BMP Is a Clinically Translatable Biomarker in FTD
CSF BMP IS A CLINICALLY TRANSLATABLE BIOMARKER IN FTD CSF BMP correlated brain BMP in Grn KO CSF BMP levels are decreased in FTD patients and can be rescued with PTV:PGRN Low dose 4, 24 hours di-18:1 BMP (CSF) di-22:6 BMP (CSF) CSF BMP Brain:CSF BMP correlation 24 hours HC Non-Grn Grn HC Non-Grn Grn
Slide 85: Modality-Based Brain Delivery Platforms Enabled by TV
MODALITY-BASED BRAIN DELIVERY PLATFORMS ENABLED BY TV Antibody Transport Vehicle Enzyme Transport Vehicle § Deliver antibodies in bivalent or bispecific § Deliver enzymes to the brain format to the brain § Treat neuronopathic symptoms of § Natural IgG structure and properties lysosomal storage disea
Slide 86: Oligonucleotide Transport Vehicle (OTV) Platform
OLIGONUCLEOTIDE TRANSPORT VEHICLE (OTV) PLATFORM SUCCESSFUL SITE-SPECIFIC OTV CONJUGATION + DAR = Drug Antibody Ratio Oligo Sequence / DAR 1 Chemistry Fab Binding Target Conjugation Site / Chemistry TfR Binding Affinity DAR 0 DAR 2 OTV OTV is a modular platform with multiple properties that can be o
Slide 87: OTV Knocks Down Target in CNS with Systemic Administration
OTV KNOCKS DOWN TARGET IN CNS WITH SYSTEMIC ADMINISTRATION Cortex Cortex Spinal Cord 150 : Single dose 150 : Single dose ATV Control) ATV Control) (% ATV:BACE1) (%ATV:BACE1) : Multi dose : Multi dose OTV 100 100 Malat1 mRNA (% mRNA (% Malat1 mRNA 50 50 Malat1 Malat1 ns ns * **** ns ns * **** 0 0 ATV
Slide 88: OTV Has Broad Potential in a Range of Indications
OTV HAS BROAD POTENTIAL IN A RANGE OF INDICATIONS OTV Potential Spans Across: APP Indications LRRK2 • Alzheimer’s disease MAPT SNCA • Parkinson’s disease ApoE4 • Huntington’s disease SOD1 HTT • Amyotrophic lateral sclerosis (ALS) C9orf72 • Other Neurodegenerative/ FUS mHTT SNP1 Neuromuscular disorde
Slide 89: Discovery TV Programs Conclusions
DISCOVERY TV PROGRAMS CONCLUSIONS • The TV platform has potential for broad applicability and is capable of delivering a range of therapeutics to the CNS • TV technology can enhance activity for antibody targets – ATV:Aβ displays significantly improved engagement of plaques in mouse model of Alzheim
Slide 90: Unlocking the Potential of the TV Platform
Unlocking the Potential of the TV Platform Alex Schuth, MD, COO
Slide 91: Broad Potential for a Wide Range of Indications and Targets
BROAD POTENTIAL FOR A WIDE RANGE OF INDICATIONS AND TARGETS CURRENT FUTURE FOCUS OPPORTUNITIES NEUROLOGY CURRENT PLATFORMS e.g., pain, epilepsy, NEURO- neuropsychiatry, DEGENERATION neuromuscular e.g., AD, PD, ALS Enzymes Proteins Antibodies Oligos Novel RMT Other Targets Gene Therapies Modalities O
Slide 92: Our TV Portfolio
OUR TV PORTFOLIO DRUG DEVELOPMENT PROGRAM TARGET DRUG CANDIDATE DISEASE INDICATION PARTNER Drug Discovery IND-Enabling Early Clinical Late Clinical Approved ATV – Antibody Transport Vehicle TREM2 DNL919 Alzheimer’s Takeda Abeta ATV:Abeta Alzheimer’s Biogen Tau ATV:Tau Alzheimer’s Takeda Alpha-Synucl
Slide 93: Key TV Partnerships
Enabling collaboration KEY TV PARTNERSHIPS Development/commercial collaboration TV engineering and platform IP Research collaboration on select TV-enabled targets Therapeutic mAb discovery Discovery of novel AAV capsids to enable BBB-crossing therapeutics Two TV platform programs, including ATV:Abet
Slide 94: Collaborations Realize Value and Enable New Opportunities
COLLABORATIONS REALIZE VALUE AND ENABLE NEW OPPORTUNITIES TAKEDA (JANUARY 2018) BIOGEN (AUGUST 2020) • Exclusive option to three TV programs • LRRK2 co-development/co-commercialization • PTV:PRGN • TV Option agreement • ATV:TREM2 • Exclusive option to two TV programs (incl. • ATV:Tau ATV:Abeta) • Op
Slide 95: Value Unlocked Through Data and Partnerships
VALUE UNLOCKED THROUGH DATA AND PARTNERSHIPS Broader Neurological Disease OTV Alzheimer’s Impact & Value Bivalent ATV Parkinson’s Oncology DNL310 PTV (ETV:IDS) 10-30x Brain ETV Exposure Transport Vehicle Lysosomal Storage Diseases, FTD TfR binding Hunter Syndrome 2000 - 2015 2015 2017 End of 2020 20
Slide 96: Thank You
=) Oo > x Zz <x < =
Slide 97: JENALI
JENALI
Denali Therapeutics — Denali Blood-Brain Barrier Transport Vehicle Webinar (October 2020) on 6ix